Project Grant R01HL177834
Award Date 8/15/25
Completion Date 5/31/30
Dollars Obligated $753K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Winston-Salem, NC 27157, USA
Similar Awards
- The federal Project Grant award of $783,661.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a pragmatic, randomized clinical trial to evaluate the effectiveness and safety of oral midodrine as a vasopressor-sparing agent in patients with sepsis-associated hypotension. The study, conducted by the Mayo Clinic, aims to provide an alternative to intravenous vasopressors and reduce the burden of intensive care unit (ICU) stays for these...
- This Project Grant award of $750,561 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund the SMART-SEPSIS study. The study aims to use electronic health record data and artificial intelligence/machine learning to model individual patient response to sepsis treatment and promote early but reasoned application of the hour-1 sepsis treatment bundle for patients with suspected community-onset lung sepsis. The goal is...
- The National Heart Lung and Blood Institute, under its Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $412,250 project grant to Arizona State University (ASU) to develop a real-time, automated smart catheter analyzer for early identification of sepsis through continuous monitoring of urine biomarkers. This non-invasive approach aims to enable rapid sepsis diagnosis, within 200 minutes, to support quick clinical intervention and preservation of heart and lung...
- This federal Project Grant award of $243,750.00, awarded on August 25, 2025 by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to determine if plasma renin can function as a predictive and prognostic biomarker in sepsis-induced hypotension. The University of Pennsylvania, as the awardee, will perform a secondary analysis of the NHLBI CLOVERS trial to evaluate if plasma renin as a marker of tissue perfusion is associated with response to...
- This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...
- This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to apply state-of-the-art methods to evaluate the effectiveness of mechanical circulatory support (MCS) devices in treating acute myocardial infarction complicated by cardiogenic shock (AMI-CS). The $817,358 award, effective from August 19, 2025 to May 31, 2029, will support the following key activities: Appending individual patient...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance precision medicine for Acute Respiratory Distress Syndrome (ARDS) and sepsis. The $2,295,984 award to the University of California, San Francisco (UCSF) will fund research to address critical unanswered questions about the distinct molecular phenotypes of ARDS and sepsis, and how to optimize real-time phenotyping and integrate analyses of phenotype-specific...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Chicago to investigate the role of the protein MMP3 in cardiac microvascular barrier dysfunction and heart failure during sepsis. The $762,950 award, effective September 15, 2025 through June 30, 2029, will fund studies to understand how the B1R/MMP3 pathway impacts cardiac microvascular integrity and cardiac function in sepsis. The...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $189,000.00 to the University of Utah to support a 5-year mentored research program and plan. The goal is to develop the principal investigator into an independent, patient-oriented clinical researcher focused on the pathophysiology of cardiogenic shock and its overlap with cardiorenal syndrome. The central hypothesis is that angiotensin II deficiency in a...
- The University of Washington was awarded a $827,909 Project Grant under the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on "Targeting Angiopoietin-Like 4 (ANGPTL4) in Severe Community Acquired Pneumonia". This grant, awarded on April 4, 2025, aims to determine the relationship between plasma ANGPTL4 levels and outcomes in patients with varying severity of community-acquired pneumonia, including viral and bacterial...